

ASX ANNOUNCEMENT

ANNUAL GENERAL MEETING UPDATE

SYDNEY, Monday, 23 November 2020, Cellmid Limited (ASX: CDY) provides the following update in relation to its Annual General Meeting ("AGM") which is being held on Monday, 30 November 2020 at 1:00 PM (AEDT).

As advised in the Notice of Annual General Meeting, which can be viewed and downloaded online at the following link: <https://cellmid.com.au/investors/asx-announcements/2020-asx-announcements/>, the physical meeting venue has a total attendance limit of 12 persons. This is to ensure that appropriate social distancing measures, in accordance with Australian state and federal government guidelines, can be adhered to.

The Company is now aware that it will have the maximum number of persons physically in attendance at the Annual General Meeting and therefore advises that any shareholder wishing to attend the AGM to do so virtually to avoid the disappointment of not being able to participate in person.

Shareholders attending the virtual meeting will be given the same opportunity to vote and ask questions as though they were in physical attendance.

For more information on how to attend the virtual meeting please see the details below and those contained within the Notice of Meeting.

Virtual Meeting

If you wish to virtually attend the AGM (which will be broadcast as a live webinar), please **pre-register** in advance for the virtual meeting here:

https://us02web.zoom.us/webinar/register/WN_3PfLqOrISfyVf8wppNYnZg

After registering, you will receive a confirmation containing information on how to attend the virtual meeting on the day of the AGM.

Shareholders will be able to vote and ask questions at the virtual meeting. Shareholders are also encouraged to submit questions in advance of the AGM to the Company. Questions must be submitted in writing to the Company Secretary, at lee.tamplin@automicgroup.com.au at least 48 hours before the AGM.

Your vote is important

All resolutions will be decided on a poll. The poll will be conducted based on votes submitted by proxy and at the Meeting.

Shareholders attending the meeting virtually and wishing to vote on the day of the meeting can find further instructions on how to do so in the Notice of Meeting. Alternatively, shareholders are strongly encouraged to complete and submit their vote by proxy by using one of the following methods:

Online	Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions: Log into the Automic website using the holding details as shown on the Proxy Form. Click on 'View Meetings' – 'Vote'. To use the online lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown on the front of the Proxy Form.
By post	Completing the Proxy Form and posting it to: Automic, GPO Box 5193, Sydney NSW 2001
By hand	Completing the Proxy Form and delivering it by hand to: Automic, Level 5, 126 Phillip Street, Sydney NSW 2000
By email	Completing the Proxy Form and emailing it to: meetings@automicgroup.com.au

Your Proxy instruction must be received not later than 48 hours before the commencement of the Meeting. **Proxy Forms received later than this time will be invalid.**

The Chair intends to vote all open proxies in favour of all resolutions, where permitted.

Approved for release by Maria Halasz, CEO.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lynamid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured access to a range of SARS-CoV-2 antibody and nucleotide tests, both point of care and laboratory based, from various suppliers.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.